Imelda Vzw | Study Cardiology
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy.
The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
918 participants in 3 patient groups
Loading...
Central trial contact
Clinical Trial Disclosure & Transparency
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal